Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 23

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 23
---
,210 shares of Common Stock issuable upon the exercise of options at a weighted average  
 exercise price of $7.21 per share.                                                          |

* On July
7, 2025, the Company converted $16.1 million in convertible promissory notes into an aggregate of 5.36 million shares of Common Stock,
based on the state $3.00 per share conversion price.

Unless otherwise indicated,
all information in this prospectus reflects the
Reverse Stock Split and assumes no issuance of the outstanding contingent consideration described
above.

<div align='center'>S-15

DESCRIPTION OF SECURITIES</div>

In this offering,
we are offering shares of our Common Stock.

Authorized Capital Stock

Our authorized
capital stock consists of 350,000,000 shares of
Common Stock, par value $0.0001 per share. As of the date of this prospectus, we had 23,430,653
shares of Common Stock outstanding.

Common Stock

Voting

For all
matters submitted to a vote of stockholders, each holder of Common Stock is entitled
to one vote for each share registered in his or her
name on our books. Our Common Stock does not have
cumulative voting rights. As a result, holders
of a majority of our outstanding Common Stock can
elect all of the directors who are up for election in a particular
year.

Dividends

Each stockholder is entitled to
receive the dividends as may be declared by our board of directors out of funds legally available for dividends. Our board of directors
is not obligated to declare a dividend. Any future dividends will be subject to the discretion of our board of directors and will depend
upon, among other things, future earnings, the operating and financial condition of our Company, its capital requirements, general business
conditions and other pertinent factors.

Liquidation and Dissolution

Each stockholder is entitled in
the event of liquidation, to share pro rata in any distribution of our assets after payment of liabilities, subject to the rights and
preferences of the holders of any outstanding shares of any series of our preferred stock.

Other Rights and Restr ictions

Holders of our Common
Stock do not have preemptive or subscription rights,
and they have no right to convert their Common
Stock into any other securities. Our Common Stock
is not subject to redemption
by us. The rights, preferences and privileges of common stockholders are subject to the
rights of the stockholders of any series of Preferred